Wall Street analyst estimates for Capricor Therapeutics, Inc. (CAPR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.14 | ||
| 2026-08-14 | $-0.70 | $-0.59 | -18.9% |
| 2026-05-12 | $-0.59 | $-0.55 | -7.3% |
| 2026-03-12 | $-0.62 | $-0.51 | -21.6% |
| 2025-11-10 | $-0.54 | $-0.54 | +0.0% |
| 2025-08-11 | $-0.57 | $-0.48 | -18.7% |
| 2025-05-13 | $-0.53 | $-0.33 | -60.6% |
| 2025-03-19 | $-0.16 | $-0.31 | +48.4% |
Valuation Ratios
| Price / Book | 1.85 |
| EV / EBITDA | 0.52 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $2.7M | $1.7M | $1.0M | $310250 | $244898 | $2.6M | $25.2M | $22.3M | 0 |
| Cost of Revenue | $16.0M | 0 | 0 | $5.1M | 0 | 0 | $21.8M | $36.4M | $50.0M | 0 |
| Gross Profit | -$12.9M | $2.7M | $1.7M | -$4.1M | $310250 | $244898 | -$19.3M | -$11.3M | -$27.7M | 0 |
| Research & Development | $16.0M | $10.8M | $12.1M | $5.1M | $8.5M | $13.6M | $21.8M | $36.4M | $50.0M | $84.5M |
| Selling, General & Admin | $4.9M | $4.8M | $4.9M | $3.6M | $5.5M | $7.6M | $10.4M | $12.8M | $14.9M | $22.7M |
| Operating Expenses | $4.9M | $4.8M | $17.0M | $3.6M | $14.0M | $21.2M | $10.4M | $12.8M | $14.9M | $108.1M |
| Operating Income | -$17.0M | -$12.9M | -$15.3M | -$7.7M | -$13.7M | -$20.9M | -$29.7M | -$24.1M | -$42.6M | -$108.1M |
| EBITDA | -$18.3M | $3.0M | -$15.2M | -$7.6M | -$13.5M | -$19.8M | -$28.5M | -$21.2M | -$39.0M | -$100.1M |
| Interest Expense | $344665 | $398807 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.0M |
| Pre-tax Income | -$18.8M | $2.4M | -$15.2M | -$7.6M | -$13.7M | -$20.0M | -$29.0M | -$22.3M | -$40.5M | -$105.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$18.8M | $2.4M | -$15.2M | -$7.6M | -$13.7M | -$20.0M | -$29.0M | -$22.3M | -$40.5M | -$105.0M |
| EPS | $-10.14 | $1.00 | $-5.17 | $-2.06 | $-0.88 | $-0.87 | $-1.18 | $-0.83 | $-1.15 | $-2.26 |
| EPS (Diluted) | $-10.14 | $0.90 | $-5.17 | $-2.06 | $-0.88 | $-0.87 | $-1.18 | $-0.83 | $-1.15 | $-2.26 |
| Shares Outstanding (Diluted) | $1.9M | $2.7M | $2.9M | $3.7M | $15.6M | $23.1M | $24.6M | $26.8M | $35.2M | $46.5M |
Price
| Price | $8.56 |
| Market Cap | $492M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACHV · ALLO · ARCT · CABA · EDIT · IMMP · LXEO
Explore sector: Healthcare · Biotechnology
More sections of CAPR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks